Daiichi Sankyo To Be Engaged In Ranbaxy’s Problems With U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo plans to come to the aid of its recently acquired Ranbaxy Laboratories as the Indian drug maker attempts to handle accusations by U.S. FDA. Daiichi Sankyo President Takashi Shoda said his company would be actively engaged in the dealings between the two parties. The FDA blackballed two Ranbaxy plants earlier this year on grounds the drug maker submitted falsified data. Shoda said Daiichi is completing plans to address the problems cited by the FDA. (Click here for more - a subscription may be required